Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis.
Anti-citrullinated protein antibodies (ACPA) have been shown to cause platelet activation in vitro, through the low-affinity immunoglobulin G (IgG) receptor (FcγRIIa) on platelets. Platelet activation via engagement of FcγRIIa results in proteolytic cleavage and shedding of platelet specific glycopr...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5687752?pdf=render |
id |
doaj-5137a43b12ce4264ab6bf0520a88c604 |
---|---|
record_format |
Article |
spelling |
doaj-5137a43b12ce4264ab6bf0520a88c6042020-11-24T21:52:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011211e018802710.1371/journal.pone.0188027Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis.John R StackAnne MadiganLaura HelbertEimear DunneElizabeth E GardinerRobert K AndrewsRoisin FinanElizabeth SmythDermot KennyGeraldine M McCarthyAnti-citrullinated protein antibodies (ACPA) have been shown to cause platelet activation in vitro, through the low-affinity immunoglobulin G (IgG) receptor (FcγRIIa) on platelets. Platelet activation via engagement of FcγRIIa results in proteolytic cleavage and shedding of platelet specific glycoprotein VI (GPVI) which can be detected in the plasma as soluble GPVI (sGPVI). We hypothesized that plasma levels of sGPVI would be increased among patients with seropositive RA as a consequence of antibody-induced platelet activation and GPVI shedding.Samples from 84 patients with RA (65 seropositive and 19 seronegative) and 67 healthy controls were collected prospectively and analysed for sGPVI using a standardised ELISA.Patients with seropositive RA had significantly higher levels of sGPVI compared to seronegative RA and controls. Median (IQR) sGPVI levels were 4.2 ng/ml (3.2, 8.0) in seropositve RA, 2.2 ng/ml (1.5, 3.5) in seronegative RA and 2.2 ng/ml (1.6, 3.4) in controls (p<0.0001). sGPVI levels correlated with ACPA titres (r = 0.32, p = 0.0026) and with RF titres (r = 0.48, p<0.0001).Plasma sGPVI, a specific marker of platelet activation is increased among patients with seropositive RA.http://europepmc.org/articles/PMC5687752?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
John R Stack Anne Madigan Laura Helbert Eimear Dunne Elizabeth E Gardiner Robert K Andrews Roisin Finan Elizabeth Smyth Dermot Kenny Geraldine M McCarthy |
spellingShingle |
John R Stack Anne Madigan Laura Helbert Eimear Dunne Elizabeth E Gardiner Robert K Andrews Roisin Finan Elizabeth Smyth Dermot Kenny Geraldine M McCarthy Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. PLoS ONE |
author_facet |
John R Stack Anne Madigan Laura Helbert Eimear Dunne Elizabeth E Gardiner Robert K Andrews Roisin Finan Elizabeth Smyth Dermot Kenny Geraldine M McCarthy |
author_sort |
John R Stack |
title |
Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. |
title_short |
Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. |
title_full |
Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. |
title_fullStr |
Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. |
title_full_unstemmed |
Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. |
title_sort |
soluble glycoprotein vi, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
Anti-citrullinated protein antibodies (ACPA) have been shown to cause platelet activation in vitro, through the low-affinity immunoglobulin G (IgG) receptor (FcγRIIa) on platelets. Platelet activation via engagement of FcγRIIa results in proteolytic cleavage and shedding of platelet specific glycoprotein VI (GPVI) which can be detected in the plasma as soluble GPVI (sGPVI). We hypothesized that plasma levels of sGPVI would be increased among patients with seropositive RA as a consequence of antibody-induced platelet activation and GPVI shedding.Samples from 84 patients with RA (65 seropositive and 19 seronegative) and 67 healthy controls were collected prospectively and analysed for sGPVI using a standardised ELISA.Patients with seropositive RA had significantly higher levels of sGPVI compared to seronegative RA and controls. Median (IQR) sGPVI levels were 4.2 ng/ml (3.2, 8.0) in seropositve RA, 2.2 ng/ml (1.5, 3.5) in seronegative RA and 2.2 ng/ml (1.6, 3.4) in controls (p<0.0001). sGPVI levels correlated with ACPA titres (r = 0.32, p = 0.0026) and with RF titres (r = 0.48, p<0.0001).Plasma sGPVI, a specific marker of platelet activation is increased among patients with seropositive RA. |
url |
http://europepmc.org/articles/PMC5687752?pdf=render |
work_keys_str_mv |
AT johnrstack solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT annemadigan solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT laurahelbert solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT eimeardunne solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT elizabethegardiner solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT robertkandrews solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT roisinfinan solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT elizabethsmyth solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT dermotkenny solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis AT geraldinemmccarthy solubleglycoproteinviaspecificmarkerofplateletactivationisincreasedintheplasmaofsubjectswithseropositiverheumatoidarthritis |
_version_ |
1725876298420584448 |